-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NvNZJYT/5T0AL/caW6nxzCXr5M6owOlRh7Y98MzVIgMfMLrt2OLGihIraDc/M6Cu 48gDQP/N74kelZK/7eql5A== 0001209191-10-004002.txt : 20100120 0001209191-10-004002.hdr.sgml : 20100120 20100120172340 ACCESSION NUMBER: 0001209191-10-004002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100115 FILED AS OF DATE: 20100120 DATE AS OF CHANGE: 20100120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brege Laura CENTRAL INDEX KEY: 0001365619 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28298 FILM NUMBER: 10537017 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ONYX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012140 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943154463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 5105976500 MAIL ADDRESS: STREET 1: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-01-15 0 0001012140 ONYX PHARMACEUTICALS INC ONXX 0001365619 Brege Laura C/O ONYX PHARMACEUTICALS, INC. 2100 POWELL STREET EMERYVILLE CA 94608 0 1 0 0 EVP and Chief Business Officer Common Stock 2010-01-15 4 M 0 12500 15.44 A 30293 D Common Stock 2010-01-15 4 S 0 12500 30.12 D 17793 D Stock Option (Right to Buy) 15.44 2010-01-15 4 M 0 12500 0.00 D 2016-06-12 Common Stock 12500 112500 D Includes shares purchased through the issuer's ESPP. Shares sold pursuant to a 10b5-1 plan. Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter. /s/ Matthew K. Fust, Attorney-in-fact 2010-01-19 -----END PRIVACY-ENHANCED MESSAGE-----